August 8, 2022
Webinar: Assessing Drug-induced Gut Toxicity In Vitro
Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin, Ph.D, Chief Scientific Officer, Altis Biosystems discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.
April 1, 2022
The Next Big Thing in Pharma
Bill Thelin, Ph.D, Chief Scientific Officer at Altis Biosystems discusses the future of healthcare, and what's the next big thing in pharma. Bill focuses on how the development of microphysiological systems will support the development of drugs from discovery to humans.
November 4, 2021
Webinar: A novel in vitro stem cell platform for studying intestinal inflammation
Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin, Ph.D, Chief Scientific Officer, Altis Biosystems discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.
March 2, 2021
A Gut Feeling About the Future of Healthcare
Scott Magness, Chief Scientific Advisor at Altis Biosystems, discusses the impact that RepliGut®—a human stem cell-derived platform that recreates the intestinal epithelium—may have on stem cell research and drug testing. Watch previous video.